Clinical trial of nasal vaccine against COVID-19 launched in Moscow
A clinical trial of an intranasal form of the vaccine against coronavirus infection created by the Generium company has started in Moscow, involving 660 people – TASS reports
“Today, on the basis of six Moscow polyclinics, we began a clinical trial of a nasal vaccine developed by the Generium company. In total, 660 people will take part in it: about 400 of them in Moscow medical institutions while the remaining in 11 centres throughout Russia. This vaccine is identical in composition of active ingredients to Sputnik V – intended for intramuscular injection,” reads the message posted on the website of the Mayor of Moscow.
According to Anastasia Rakova, Deputy Mayor of Moscow for Social Development, earlier, on the basis of polyclinics, a study of a nasal vaccine against COVID-19 – developed at the N.F. Gamaleya Research Centre – had started.
In the world for all the time the diagnosis of COVID-19 was confirmed for more than 414 million cases. The total number of global deaths due to coronavirus exceeded 5.8 million. 336.1 million people who had previously been diagnosed with COVID-19 recovered.
